IGI Laboratories (IG)
IGI Laboratories Revenues: 2.095M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IG Revenues Rankings
| Overall | 3rd percentile | 4263 of 4432 |
| Sector | 16th percentile | 391 of 470 in Healthcare |
| Industry | 28th percentile | 95 of 132 in Biotechnology |
IG Revenues Range, Past 5 Years
| Minimum | 0.594M | Mar 2009 |
| Maximum | 2.113M | Sep 2011 |
| Average | 1.342M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these IG related companies
IG News
IGI Laboratories (IG) Submits 5th Abbreviated New Drug Application with FDA in 2011
Dec 29, 8:02AM Street Insider
Dec 29, 8:02AM Street Insider
IGI Laboratories and NeoStrata Company, Inc. Extend Turnkey Supply Agreement
Dec 22, 8:00AM Business Wire
Dec 22, 8:00AM Business Wire
IGI Laboratories, Inc. and Medimetriks Pharmaceuticals, Inc. Enter Long Term Strategic Partnership
Dec 08, 8:00AM Business Wire
Dec 08, 8:00AM Business Wire
CORRECTING and REPLACING TriPoint Global Research Publishes Research Report on IGI, Laboratories, Inc.
Jun 14, 4:53PM Business Wire
Jun 14, 4:53PM Business Wire
TriPoint Global Research Publishes Research Report on IGI, Laboratories, Inc.
Jun 14, 3:25PM Business Wire
Jun 14, 3:25PM Business Wire
$PPG $IG $DD These stocks are riding below their 52-week highs via http://equities.com http://stk.ly/k5xZYc
about 352 days ago by micstockwell
about 352 days ago by micstockwell
$IG $1.18 Lawrence Nadya officer (Exec. VP-Sales and Marketing) S 25,000 @ $1.19 amnt $29,750 proc'd $250 5/11/2011
about 382 days ago by canarionyc
about 382 days ago by canarionyc
IGI Laboratories registers to sell 881,331 shares of common stock for holders
Apr 20, 5:25PM FlyOnTheWall
Apr 20, 5:25PM FlyOnTheWall
$IG Lawrence Nadya officer (Exec. VP-Sales and Markt) sold 5,000 @ $1.60 totl $8,000.00 2010-11-16 ( filed 2010-12-080)
about 527 days ago by canarionyc
about 527 days ago by canarionyc
IGI Laboratories $IG hitting 52-week highs. Company recently
announced its first ANDA Submission.
about 603 days ago by BioMedReports
about 603 days ago by BioMedReports
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IG | 1.04 | +0.01 | +0.97% | 41.08M |
| IFT | 4.18 | +0.00 | +0.00% | 88.62M |
| IFSM | 31.41 | +0.43 | +1.39% | |
| IFSIA | 12.80 | -0.05 | -0.39% | 840.78M |
| LTS | 1.45 | -0.02 | -1.36% | 270.61M |
| LTRX | 2.08 | +0.01 | +0.48% | 22.01M |
| LTRE | 4.60 | -0.15 | -3.16% | 64.17M |
| LTPZ | 69.68 | +0.84 | +1.22% | |
| LTON | 1.51 | +0.03 | +2.03% | 60.74M |
| LTM | 43.48 | -0.02 | -0.05% | 1.859B |
